{"filing":{"accession_number":"0001104659-26-111391","cik":"0001819411","ticker":"GANX","company_name":"Gain Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-28","report_date":"2026-09-22","primary_document":"tm2626106d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1819411/000110465926111391/tm2626106d1_8k.htm"},"events":[{"id":35483,"run_id":32681,"accession_number":"0001104659-26-111391","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"The filing discloses both the resignation of Gianluca Fuggetta as principal financial officer (effective September 30, 2026) and the appointment of Gene Mack as interim Chief Financial Officer (effective October 1, 2026). While both events occur, the principal disclosed action centers on the appointment of Mack to assume the duties of principal financial officer and principal accounting officer. The appointment of an interim CFO is material to investors as it signals a change in financial leadership and potential operational continuity concerns, particularly given the company is conducting an ongoing search for a permanent replacement.","company_name":"Gain Therapeutics, Inc.","ticker":"GANX","filing_date":"2026-09-28","form":"8-K","submitted_at":null,"items":[{"id":39546,"accession_number":"0001104659-26-111391","item_number":"5.02","item_title":"Departure of Directors or Certain","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses both the resignation of Gianluca Fuggetta as principal financial officer (effective September 30, 2026) and the appointment of Gene Mack as interim Chief Financial Officer (effective October 1, 2026). While both events occur, the principal disclosed action centers on the appointment of Mack to assume the duties of principal financial officer and principal accounting officer. The appointment of an interim CFO is material to investors as it signals a change in financial leadership and potential operational continuity concerns, particularly given the company is conducting an ongoing search for a permanent replacement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T20:34:07.023997+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39546,"accession_number":"0001104659-26-111391","item_number":"5.02","item_title":"Departure of Directors or Certain","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses both the resignation of Gianluca Fuggetta as principal financial officer (effective September 30, 2026) and the appointment of Gene Mack as interim Chief Financial Officer (effective October 1, 2026). While both events occur, the principal disclosed action centers on the appointment of Mack to assume the duties of principal financial officer and principal accounting officer. The appointment of an interim CFO is material to investors as it signals a change in financial leadership and potential operational continuity concerns, particularly given the company is conducting an ongoing search for a permanent replacement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T20:34:07.023997+00:00","company_name":"Gain Therapeutics, Inc.","ticker":"GANX","filing_date":"2026-09-28"}]}